journal
MENU ▼
Read by QxMD icon Read
search

Endocrine-related Cancer

journal
https://www.readbyqxmd.com/read/28341725/paraneoplastic-endocrine-syndromes
#1
Georgios K Dimitriadis, Anna Angelousi, Martin O Weickert, Harpal S Randeva, Gregory A Kaltsas, Ashley B Grossman
The majority of neoplasms produce symptoms related to mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin...
March 24, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#2
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28289080/microrna-applications-for-prostate-ovarian-and-breast-cancer-in-the-era-of-precision-medicine
#3
Bethany Smith, Priyanka Agarwal, Neil A Bhowmick
The high degree of conservation in microRNA from Caenorhabditis elegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microRNA to address these changes holds significant promise. However, prostate, ovarian, and breast cancers are heterogeneous and face issues of evolving therapeutic resistance. Transforming growth factor-beta (TGF-ß) signaling axis plays an important role in the progression of each of these cancers, in part through microRNA regulation, and reciprocally, microRNA regulation of TGF-ß actions...
March 13, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28274953/incidence-of-malignant-tumours-in-patients-with-a-non-functioning-pituitary-adenoma
#4
Daniel S Olsson, Casper Hammarstrand, Ing-Liss Bryngelsson, Anna G Nilsson, Eva Andersson, Gudmundur Johannsson, Oskar Ragnarsson
Whether patients with non-functioning pituitary adenoma (NFPA) are at increased risk of developing malignant tumours has been sparsely studied and is a matter of debate. In this study, we have investigated the incidence of malignant tumours in a large and unselected group of patients with NFPA. The study was nationwide and included all patients diagnosed with NFPA between 1987-2011 (n=2,795) in Sweden, identified in the National Patient Register. Malignant tumours, occurring after the NFPA diagnosis, were identified in the Swedish Cancer Register between 1987-2014...
March 8, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28270435/timing-of-multikinase-inhibitor-initiation-in-differentiated-thyroid-cancer
#5
Marcia S Brose, Jan Wa Smit, Chia-Chi Lin, Fabian Pitoia, Marc Fellous, Yoriko DeSanctis, Martin Schlumberger, Masayuki Tori, Iwao Sugitani
There are limited treatment options for patients with radioactive iodine-refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients with radioactive iodine -refractory, progressive differentiated thyroid cancer for whom there is a decision to initiate multikinase inhibitors at study entry (cohort 1) with those for whom there is a decision to not initiate multikinase inhibitors at study entry (cohort 2)...
March 7, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249964/minimal-extrathyroidal-extension-does-not-affect-survival-of-well-differentiated-thyroid-cancer
#6
Zaid Al-Qurayshi, Mohamed Ahmed Shama, Gregory W Randolph, Emad Kandil
Differentiated thyroid cancer (DTC) with minimal extrathyroidal extension (MEE), is classified as stage III regardless of the tumor size. In this study, we aim to examine the effect of MEE on the overall survival and management of this population. Using a retrospective cohort study utilizing the National Cancer Data Base (NCDB), 2004-2012, the study population included patients, ≥ 45 years old, who underwent surgery for DTC (pT3N0M0) with MEE compared to patients with (pT2N0M0). We found a total of 9556 patients were included...
March 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249963/cell-death-response-to-anti-mitotic-drug-treatment-in-cell-culture-mouse-tumor-model-and-the-clinic
#7
Jue Shi, Timothy J Mitchison
Anti-mitotic cancer drugs include classic microtubule-targeting drugs, such as taxanes and vinca alkaloids, and the newer spindle-targeting drugs, such as inhibitors of the motor protein, Kinesin-5 (aka KSP, Eg5, KIF11), and Aurora-A, Aurora-B and Polo-like kinases. Microtubule-targeting drugs are among the first line of chemotherapies for a wide spectrum of cancers, but patient responses vary greatly. We still lack understanding of how these drugs achieve a favorable therapeutic index, and why individual patient responses vary...
March 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249962/local-optometrists-are-a-major-source-of-referrals-to-a-pituitary-tumour-clinic
#8
Haval Surchi, Bahram Jafar-Mohammadi, Aparna Pal, Simon Cudlip, Ashley B Grossman
Pituitary adenomas can be identified pathologically in some 20-25% of autopsy specimens, but only around 1/1000 of the population have clinically significant tumours.Classic bitemporal hemianopia occurs as tumour expands. These visual symptoms are the most common objective manifestations of non-functioning pituitary adenomas, and demand urgent decompression to increase the probability of a complete normalisation of visual function. Delayed diagnosis may lead to irreversible visual loss.The onset of the visual deficit is usually gradual such that many patients might not seek medical consultation for months or even years...
March 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28235956/genomic-complexity-and-targeted-genes-in-anaplastic-thyroid-cancer-cell-lines
#9
Eleanor Louise Woodward, Andrea Biloglav, Naveen Ravi, Minjun Yang, Lars Ekblad, Johan Wennerberg, Kajsa Paulsson
Anaplastic thyroid cancer (ATC) is a highly malignant disease with very short median survival times. Few studies have addressed the underlying somatic mutations, and the genomic landscape of ATC thus remains largely unknown. In the present study, we have ascertained copy number aberrations, gene fusions, gene expression patterns, and mutations in early-passage cells from ten newly established ATC cell lines using single nucleotide polymorphism (SNP) array analysis, RNA-sequencing and whole exome sequencing...
February 24, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28223365/the-eortc-module-for-quality-of-life-in-patients-with-thyroid-cancer-phase-iii
#10
Susanne Singer, Susan Jordan, Laura D Locati, Monica Pinto, Iwona M Tomaszewska, Claudia Araujo, Eva Hammerlid, E Vidhubala, Olga Husson, Naomi Kiyota, Christine Brannan, Dina Salem, Eva Gamper, Juan Ignacio Arraras, Georgios Ioannidis, Guy Andry, Johanna Inhestern, Vincent Gregoire, Lisa Licitra
We pilot-tested a questionnaire measuring health related quality of life (QoL) in thyroid cancer patients to be used with the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C30. A provisional questionnaire with 47 items was administered to patients treated for thyroid cancer within the last 2 years. Patients were interviewed about time and help needed to complete the questionnaire and whether they found the items understandable, confusing, or annoying. Items were kept in the questionnaire if they fulfilled pre-defined criteria: relevant to the patients, easy to understand, not confusing, few missing values, neither floor nor ceiling effects, and high variance...
February 21, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28223364/protein-kinase-c-regulates-twist1-expression-via-nf-%C3%AE%C2%BAb-in-prostate-cancer
#11
Masaki Shiota, Akira Yokomizo, Ario Takeuchi, Eiji Kashiwagi, Takashi Dejima, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Masatoshi Eto
The progression of prostate cancer to metastatic and castration-resistant disease represents a critical step. We previously showed that protein kinase C (PKC) activation followed by Twist1 and androgen receptor (AR) induction played a critical role in castration resistance, but the precise molecular mechanism remains unknown. This study aimed to elucidate the relevant molecular mechanism, focusing on NF-κB transcription factor. We examined the activity of NF-κB after PKC inhibition, and the expression of Twist1 and AR after inhibition of NF-κB in human prostate cancer cells...
February 21, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28213567/vitamin-d-receptor-as-a-target-for-breast-cancer-therapy
#12
Alyson Murray, Stephen Madden, Naoise C Synnott, Rut Klinger, Darran O'Connor, Norma O'Donovan, William Gallagher, John Crown, Michael Duffy
Considerable epidemiological evidence suggests that high levels of circulating vitamin D (VD) are associated with a decreased incidence and increased survival from cancer, i.e., VD may possess anti-cancer properties. The aim of this investigation was therefore to investigate the anti-cancer potential of a low calcemic vitamin D analogue, i.e., inecalcitol and compare it with the active form of vitamin D, i.e., calcitriol, in a panel of breast cancer cell lines (n = 15). Using the MTT assay, IC50 concentrations for response to calcitriol varied from 0...
February 17, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28209634/cognitive-decline-in-prostate-cancer-patients-undergoing-adt
#13
Niamh Liana Mundell, Robin M Daly, Helen Macpherson, Steve F Fraser
Androgen deprivation therapy (ADT) is an effective and widely prescribed treatment for prostate cancer (PCa), but it is associated with multiple treatment induced adverse effects that impact on various musculoskeletal and cardiometabolic health outcomes. Emerging research has shown that ADT is also associated with cognitive impairment, which has been linked to a loss of independence, increased falls and fracture risk and greater use of medical services. The aim of this review is to outline the evidence related to the effect of ADT use on cognitive function, and propose a role for exercise training as part of usual care to prevent and/or manage cognitive impairments for PCa survivors on ADT...
February 16, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28193698/the-innate-and-adaptive-infiltrating-immune-systems-as-targets-for-breast-cancer-immunotherapy
#14
Andrew Mk Law, Elgene Lim, Christopher Ormandy, David Gallego-Ortega
A cancer cell-centric view has long dominated the field of cancer biology. Research efforts have focussed on aberrant cancer cell signalling pathways and on changes to cancer cell DNA. Mounting evidence demonstrates that many cancer-associated cell types within the tumour stroma co-evolve and support tumour growth and development, greatly modifying cancer cell behaviour, facilitating invasion and metastasis, and controlling dormancy and sensitivity to drug therapy. Thus, these stromal cells represent potential targets for cancer therapy...
February 13, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28148541/silencing-the-roadblocks-to-effective-tnbc-treatments-by-sirna-nanoparticles
#15
Jenny G Parvani, Mark W Jackson
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function in vitro, however limitations were associated with its utility in vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple negative breast cancer (TNBC)...
February 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28143811/lipomatous-tumours-in-adrenal-gland-who-updates-and-clinical-implications
#16
Alfred Lam
Adrenal lipomatous tumour is a group of adrenal tumours with a significant component of adipose tissue. According to the current World Health Organization (WHO) classification of tumours of endocrine organs, adrenal myelolipoma is the only entity amongst the group of tumours being described. In the literature, other more recently documented adrenal lipomatous tumours included 24 lipomas, 32 teratomas and 16 angiomyolipomas. Rare fatty tumours of the adrenal gland comprised liposarcoma, hibernoma, adrenocortical tumours with fat component and rare adrenal tumours with fat component...
January 31, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28137980/nelfinavir-inhibits-proliferation-and-induces-dna-damage-in-thyroid-cancer-cells
#17
Kirk Jensen, Athanasios D Bikas, Aneeta Patel, Yevgeniya Kushchayeva, John Costello, Dennis McDaniel, Kenneth Burman, Vasily Vasko
The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. We examined the effects of NFV on cancer cells that derived from follicular (FTC), papillary (PTC) and anaplastic (ATC) thyroid cancers. NFV (1-20 μM) was tested in FTC133, BCPAP and SW1736 cell lines. The effects of NFV on cell proliferation were determined in vitro using real-time microscopy and by flow cytometry. DNA damage, apoptotic cell death, and expression of molecular markers of epithelial-mesenchymal transition (EMT) were determined by Western blot and real-time PCR...
January 30, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28104681/copy-number-variations-of-e2f1-a-new-genetic-risk-factor-for-testicular-cancer
#18
Maria Santa Rocca, Andrea Di Nisio, Arianna Marchiori, Marco Ghezzi, Giuseppe Opocher, Carlo Foresta, Alberto Ferlin
Testicular germ cell tumor (TGCT) is one of the most heritable forms of cancer. In last years many evidence suggested that constitutional genetic factors, mainly single nucleotide polymorphisms, can increase its risk. However, the possible contribution of copy-number variations (CNVs) in TGCT susceptibility has not been substantially addressed. Indeed, an increasing number of studies have focused on the effect of CNVs on gene expression and on the role of these structural genetic variations as risk factors for different forms of cancer...
January 19, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28104680/evaluation-of-thyroseq-v2-performance-in-thyroid-nodules-with-indeterminate-cytology
#19
Pablo Valderrabano, Laila Khazai, Marino E Leon, Zachary J Thompson, Zhenjun Ma, Christine H Chung, Julie E Hallanger-Johnson, Kristen J Otto, Kara D Rogers, Barbara Centeno, Bryan McIver
ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pre-test risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of the Bethesda system). We evaluated ThyroSeq v2 performance in a cohort of patients with ITNs seen at our Academic Cancer Center from September 2014 to April 2016, in light of the new diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Our study included 182 patients (76% female) with 190 ITNs consecutively tested with ThyroSeq v2...
January 19, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28062546/the-clinical-importance-of-quantifying-fat-distribution-during-androgen-deprivation
#20
Stephen John Foulkes, Robin M Daly, Steve Fraser
Androgen deprivation therapy (ADT) is now considered a mainstay in the treatment of metastatic and locally advanced prostate cancer (PCa). Despite well-established benefits of ADT in relation to overall survival, this treatment has been associated with a number of adverse effects, particularly with regard to key cardiometabolic risk factors including the development of insulin resistance, dyslipidaemia and increases in total and regional fat mass. In non-ADT populations, increased levels of visceral adipose tissue (VAT) are thought to be a key mediator of the increased cardiometabolic risk associated with weight gain, but this has received limited attention in men treated with ADT...
January 6, 2017: Endocrine-related Cancer
journal
journal
32030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"